Izrael -
hebrejština -
Ministry of Health
מרקאין ספיינל % 0.5 הבי
padagis israel agencies ltd, israel - bupivacaine hydrochloride - תמיסה להזרקה - bupivacaine hydrochloride 5 mg/ml - bupivacaine - bupivacaine - spinal anaesthesia for surgery, e.g. urological and lower limb surgery, lasting 2-3 hours, abdominal surgery lasting 45-60 minutes.
Izrael -
hebrejština -
Ministry of Health
מרקאין ספינל % 0.5
padagis israel agencies ltd, israel - bupivacaine hydrochloride - תמיסה להזרקה - bupivacaine hydrochloride 5 mg/ml - bupivacaine - bupivacaine - spinal anaesthesia for surgery.
Izrael -
hebrejština -
Ministry of Health
minus 417 -קרם יחודי למילוי וטיפול מסיר של קמטי הבעה והתבגרות
א.ל. ארמן יצור תמרוקים בעמ - צמצום קמטים וקמטוטים
Izrael -
hebrejština -
Ministry of Health
minuteman
medoc ltd, advanced medical systems - מומחה - מישתל מלעורי להרחקה וקיבוע בין שתי חוליות בעמוד השדרה.
Izrael -
hebrejština -
Ministry of Health
פבוניה בוטניקה - עטיפת גוף קרם פרש פאפאיה- אננס
פבוניה ישראל בעמ - צמצום קמטים וקמטוטים
Izrael -
hebrejština -
Ministry of Health
בינוקריט 1000 יחבל 0.5 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
Izrael -
hebrejština -
Ministry of Health
בינוקריט 2000 יחבל 1 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
Izrael -
hebrejština -
Ministry of Health
בינוקריט 30000 יחבל 0.75 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob